Antiviral activity of cationic amphiphilic drugs

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 5, 2017, Pages 483-492

  Salata, Cristiano ^a   Calistri, Arianna ^a   Parolin, Cristina ^a   Baritussio, Aldo ^a   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Amiodarone; antivirals; cationic amphiphilic drugs; chikungunya virus; chloroquine; Crimean Congo hemorrhagic fever virus; dengue virus; ebola virus; emerging viruses; enterovirus; hepatitis C virus; Herpes simplex virus; ion channel blockers; protein kinase inhibitors; psychoactive drug; selective estrogen receptor modulators; U18666A; Zika virus

Indexed keywords

AMPHOPHILE; ANTIARRHYTHMIC AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; CATION; CATIONIC AMPHIPHILIC DRUG; PROTEIN KINASE INHIBITOR; PSYCHOTROPIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; SURFACTANT;

ANTIVIRAL ACTIVITY; CELL COMPARTMENTALIZATION; CELL MEMBRANE; DRUG ACCUMULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG USE; ENDOSOME; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; LYSOSOME; NONHUMAN; OFF LABEL DRUG USE; PHYSICAL CHEMISTRY; PLASMODIUM MALARIAE INFECTION; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; DRUG EFFECTS; DRUG REPOSITIONING; HOST PATHOGEN INTERACTION; VIROLOGY; VIRUS; VIRUS DISEASES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIMALARIALS; ANTIVIRAL AGENTS; DRUG REPOSITIONING; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE TRANSPORT MODULATORS; OFF-LABEL USE; PROTEIN KINASE INHIBITORS; PSYCHOTROPIC DRUGS; SURFACE-ACTIVE AGENTS; VIRUS DISEASES; VIRUSES;

EID: 85017454955     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1305888     Document Type: Review

References (105)

1. Calistri A, Salata C, Parolin C, et al. New generation sequencing in pathogen discovery and microbial surveillance. Expert Rev Anti Infect Ther. 2013;11(9):877–879.​​
2. Fineberg HV., Pandemic preparedness and response–lessons from the H1N1 influenza of 2009. N Engl J Med. 2014;370(14):1335–1342.
3. Gao H, Yao H, Yang S, et al. From SARS to MERS:evidence and speculation. Front Med. 2016 Oct 1;10:377–382.
4. Holmes EC, Dudas G, Rambaut A, et al. The evolution of Ebola virus:insights from the 2013-2016 epidemic. Nature. 2016;538(7624):193–200.
5. Abushouk AI, Negida A, Ahmed H., An updated review of Zika virus. J Clin Virol. 2016;84:53–58.
6. Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature. 2007;447(7142):279–283.
7. Pernet O, Schneider BS, Beaty SM, et al. Evidence for henipavirus spillover into human populations in Africa. Nat Commun. 2014;5:5342.
8. Lee B, Rota PA, eds. Henipavirus:ecology, molecular virology and pathogenesis. Springer-Verlag Berlin Heidelberg; 2012.​​
9. Keesing F, Belden LK, Daszak P, et al. Impacts of biodiversity on the emergence and transmission of infectious diseases. Nature. 2010;468(7324):647–652.
10. Preston ND, Daszak P, Colwell RR. The human environment interface:applying ecosystem concepts to health. Curr Top Microbiol Immunol. 2013;365:83–100.
11. Vigant F, Santos NC, Lee B. Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol. 2015;13:426–437.
12. Bekerman E, Einav S. Infectious disease. Combating emerging viral threats. Science. 2015;348(6232):282–283.•• An interesting paper that summarizes the different approaches to develop antiviral drugs highlighting the importance of repurposing research of approved drugs to develop effective broad-spectrum antivirals.
13. Kornhuber J, Tripal P, Reichel M, et al. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs):a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9–20.•• A comprehensive review that discusses the characteristic of CADs.
14. Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006;580(23):5533–5540.•• An older but comprehensive review that discusses the mechanisms of CADs in the phospholipidosis.
15. Bigler L, Spirli C, Fiorotto R, et al. Synthesis and cytotoxicity properties of amiodarone analogues. Eur J Med Chem. 2007;42(6):861–867.
16. Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages:structure-activity relationship. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L438–447.
17. Piccoli E, Nadai M, Caretta CM, et al. Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype. Biochem Pharmacol. 2011;82(9):1234–1249.
18. Mitterreiter S, Page RM, Kamp F, et al. Bepridil and amiodarone simultaneously target the Alzheimer’s disease beta- and gamma-secretase via distinct mechanisms. J Neurosci. 2010;30(26):8974–8983.
19. Chatelain P, Laruel R, Gillard M. Effect of amiodarone on membrane fluidity and Na+/K+ ATPase activity in rat-brain synaptic membranes. Biochem Biophys Res Commun. 1985;129(1):148–154.
20. Baritussio A, Marzini S, Agostini M, et al. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. Am J Physiol Lung Cell Mol Physiol. 2001;281(5):L1189–1199.
21. Santos DC, da Silva Garcia C, de Andrade CV, et al. Effect of U18666A on beta-glucosidase, sphingomyelinase, and beta-galactosidase activities in astrocytes of young rats. J Membr Biol. 2015;248(2):215–222.
22. Munegato D, Salata C, Calistri A, et al. Amiodarone inhibits Ebola virus replication in vitro.Poster session presented at:12th Annual Congress of the Italian Society for Virology. 2014 Sept 22-24, Orvieto (TR), Italy.
23. Cenedella RJ. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 2009;44(6):477–487.•• A comprehensive review summarizing the properties of the CAD prototype U18666A.
24. Davis W, Jr. The cholesterol transport inhibitor U18666a regulates amyloid precursor protein metabolism and trafficking in N2aAPP “Swedish” cells. Curr Alzheimer Res. 2008;5(5):448–456.
25. Pakkanen K, Salonen E, Mäkelä AR, et al. Desipramine induces disorder in cholesterol-rich membranes:implications for viral trafficking. Phys Biol. 2009;6(4):046004.• An interesting review about the implications of lipid dysregulation in viral trafficking.
26. Chapuy-Regaud S, Subra C, Requena M, et al. Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission. Biochimie. 2013;95(9):1677–1688.
27. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol. 1993;123(5):1107–1117.
28. Osman S, Taylor KA, Allcock N, et al. Detachment of surface membrane invagination systems by cationic amphiphilic drugs. Sci Rep. 2016;6:18536.
29. Mercer J, Helenius A. Gulping rather than sipping:macropinocytosis as a way of virus entry. Curr Opin Microbiol. 2012;15(4):490–499.
30. Schneider-Schaulies J, Schneider-Schaulies S. Sphingolipids in viral infection. Biol Chem. 2015;396(6–7):585–595.• A comprehensive review about the role of sphingolipids on viral replication cycle.
31. Miller ME, Adhikary S, Kolokoltsov AA, et al. Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J Virol. 2012;86(14):7473–7483.
32. Avota E, Gulbins E, Schneider-Schaulies S. DC-SIGN mediated sphingomyelinase-activation and ceramide generation is essential for enhancement of viral uptake in dendritic cells. Plos Pathog. 2011;7(2):e1001290.
33. Edinger TO, Pohl MO, Yángüez E, et al. Cathepsin W is required for escape of Influenza A virus from late endosomes. MBio. 2015;6(3):e00297.
34. Millet JK, Whittaker GR. Host cell proteases:critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134.
35. Gnirss K, Kühl A, Karsten C, et al. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. Virology. 2012;424(1):3–10.
36. Yang ST, Kreutzberger AJ, Lee J, et al. The role of cholesterol in membrane fusion. Chem Phys Lipids. 2016;199:136–143.
37. Pattanakitsakul SN, Poungsawai J, Kanlaya R, et al. Association of Alix with late endosomal lysobisphosphatidic acid is important for dengue virus infection in human endothelial cells. J Proteome Res. 2010;9(9):4640–4648.
38. Roth SL, Whittaker GR. Promotion of vesicular stomatitis virus fusion by the endosome-specific phospholipid bis(monoacylglycero)phosphate (BMP). FEBS Lett. 2011;585(6):865–869.
39. Calistri A, Salata C, Parolin C, et al. Role of multivesicular bodies and their components in the egress of enveloped RNA viruses. Rev Med Virol. 2009;19(1):31–45.
40. Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;9(8):2123–2131.
41. Salata C, Baritussio A, Munegato D, et al. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathog Dis. 2015;73(5):ftv032.• An interesting paper that reports the relation between the ability to induce the NPC-like phenotype and the antiviral activity of amiodarone as CADs prototype.
42. Madrid PB, Panchal RG, Warren TK, et al. Evaluation of Ebola Virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1(7):317–326.
43. Johansen LM, DeWald LE, Shoemaker CJ, et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci Transl Med. 2015;7(290):290ra89.•• An interesting paper reporting several CADs that inhibit Ebola GP-mediated entry.
44. Ferraris O, Moroso M, Pernet O, et al. Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. Antiviral Res. 2015;118:75–81.
45. Madrid PB, Chopra S, Manger ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. Plos One. 2013;8(4):e60579.
46. Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416–3421.
47. Yang M, Huang L, Li X, et al. Chloroquine inhibits lytic replication of Kaposi’s sarcoma-associated herpesvirus by disrupting mTOR and p38-MAPK activation. Antiviral Res. 2016;133:223–233.
48. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
49. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893.
50. Wang LF, Lin YS, Huang NC, et al. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res. 2015;35(3):143–156.
51. Balasubramanian A, Teramoto T, Kulkarni AA, et al. Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus. Antiviral Res. 2017;137:141–150.
52. Cheng H, Lear-Rooney CM, Johansen L, et al. Inhibition of Ebola and Marburg Virus entry by G Protein-Coupled Receptor Antagonists. J Virol. 2015;89(19):9932–9938.
53. Johansen LM, Brannan JM, Delos SE, et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med. 2013;5(190):190ra79.
54. Murakami Y, Fukasawa M, Kaneko Y, et al. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microbes Infect. 2013;15(1):45–55.
55. Zheng K, Chen M, Xiang Y, et al. Inhibition of herpes simplex virus type 1 entry by chloride channel inhibitors tamoxifen and NPPB. Biochem Biophys Res Commun. 2014;446(4):990–996.
56. Neveu G, Barouch-Bentov R, Ziv-Av A, et al. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. Plos Pathog. 2012;8(8):e1002845.
57. Shoemaker CJ, Schornberg KL, Delos SE, et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. Plos One. 2013;8(2):e56265.
58. Poh MK, Shui G, Xie X, et al. U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication. Antiviral Res. 2012;93(1):191–198.
59. Takano T, Tsukiyama-Kohara K, Hayashi M, et al. Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes. J Hepatol. 2011;55(3):512–521.
60. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure:treatment of a patient in intensive care. Lancet. 2015;385(9976):1428–1435.
61. Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola therapeutics during the 2014-2015 outbreak. Trends Mol Med. 2016;22(2):164–173.
62. Lanini S, Portella G, Vairo F, et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest. 2015;125(12):4692–4698.
63. Stadler K, Ha HR, Ciminale V, et al. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Am J Respir Cell Mol Biol. 2008;39(2):142–149.
64. Cheng YL, Lan KH, Lee WP, et al. Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. Clin Sci (Lond). 2013;125(9):439–448.
65. Klintworth A, Nolden T, Westhaus S, et al. Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. Antiviral Res. 2015;124:122–131.•• A paper that reports the risks of the use of recombinant models as surrogate of authentic live virus to screen the antiviral activity of chemicals.
66. Salata C, Munegato D, Piccoli E, et al. Amiodarone increases positive-strand RNA virus replication in vitro:implications for its use in patients with viral infections. J Antimicrob Chemother. 2016;71(1):280–281.•• An interesting paper reporting the ability of amiodarone to increase viral replication.
67. Schlesinger MJ, Cahill D. Verapamil and chlorpromazine inhibit the budding of Sindbis and vesicular stomatitis viruses from infected chicken embryo fibroblasts. Virology. 1989;168(1):187–190.
68. Dash PK, Agarwal A, Sharma S, et al. Development of a SYBR green I-based quantitative RT-PCR for Ross River virus:application in vector competence studies and antiviral drug evaluation. J Virol Methods. 2016;234:107–114.
69. Abdelnabi R, Neyts J, Delang L. Antiviral strategies against Chikungunya Virus. Methods Mol Biol. 2016;1426:243–253.
70. Kaptein SJ, Neyts J. Towards antiviral therapies for treating dengue virus infections. Curr Opin Pharmacol. 2016;30:1–7.
71. Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–302.
72. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention:a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11(9):677–683.
73. McClain L, Zhi Y, Cheng H, et al. Broad-spectrum non-nucleoside inhibitors of human herpesviruses. Antiviral Res. 2015;121:16–23.
74. Shivanna V, Kim Y, Chang KO. Endosomal acidification and cathepsin L activity is required for calicivirus replication. Virology. 2014;464-465:287–295.
75. Zhu YZ, Xu QQ, Wu DG, et al. Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway. J Virol. 2012;86(24):13407–13422.
76. Brouwers J, Vermeire K, Schols D, et al. Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology. 2008;378(2):306–310.
77. Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits zika virus infection in different cell models. Viruses. 2016;8(12):pii:E322.
78. Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct. 2016;34(4):191–196.
79. Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections:an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–727.
80. Chauhan A, Tikoo A. The enigma of the clandestine association between chloroquine and HIV-1 infection. HIV Med. 2015;16(10):585–590.
81. Paton NI, Goodall RL, Dunn DT, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy:a randomized controlled trial. JAMA. 2012;308(4):353–361.
82. Gignoux E, Azman AS, de Smet M, et al. Effect of artesunate-amodiaquine on mortality related to Ebola Virus disease. N Engl J Med. 2016;374(1):23–32.
83. Farias KJ, Machado PR, Muniz JA, et al. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Viral Immunol. 2015;28(3):161–169.
84. Diaconu I, Cerullo V, Escutenaire S, et al. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. J Gene Med. 2010;12(5):435–445.
85. Bhattacharyya S, Warfield KL, Ruthel G, et al. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology. 2010;401(1):18–28.
86. Daniel JA, Chau N, Abdel-Hamid MK, et al. Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis. Traffic. 2015;16(6):635–654.
87. Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477(7364):340–343.
88. Barrows NJ, Campos RK, Powell ST, et al. A screen of FDA-approved drugs for inhibitors of Zika Virus infection. Cell Host Microbe. 2016;20(2):259–270.
89. Zhao Y, Ren J, Harlos K, et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature. 2016;535(7610):169–172.
90. Nelson EA, Barnes AB, Wiehle RD, et al. Clomiphene and its isomers block Ebola Virus particle entry and infection with similar potency:potential therapeutic implications. Viruses. 2016;8(8):pii:E206.
91. García M, Cooper A, Shi W, et al. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med. 2012;4(123):123ra24.
92. Jiang B, Himmelsbach K, Ren H, et al. Subviral Hepatitis B Virus filaments, like infectious viral particles, are released via multivesicular bodies. J Virol. 2015;90(7):3330–3341.
93. Tang Y, Leao IC, Coleman EM, et al. Deficiency of niemann-pick type C-1 protein impairs release of human immunodeficiency virus type 1 and results in Gag accumulation in late endosomal/lysosomal compartments. J Virol. 2009;83(16):7982–7995.
94. Côté M, Misasi J, Ren T, et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature. 2011;477(7364):344–348.
95. Elgner F, Ren H, Medvedev R, et al. The intra-cellular cholesterol transport inhibitor U18666A inhibits the exosome-dependent release of mature hepatitis C virus. J Virol. 2016;90(24):11181-11196.​​
96. Tani H, Iha K, Shimojima M, et al. Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus. J Virol. 2014;88(13):7317–7330.
97. Yamasaki T, Suzuki A, Hasebe R, et al. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells. Plos One. 2014;9(9):e106516.
98. Lu F, Liang Q, Abi-Mosleh L, et al. Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. Elife. 2015;4:pii:e12177.
99. Ahmad N, Farman A, Badshah SL, et al. Molecular modeling, simulation and docking study of ebola virus glycoprotein. J Mol Graph Model. 2017;72:266–271.
100. Wang J, Xing X, Fang X, et al. Cationic amphiphilic drugs self-assemble to the core-shell interface of PEGylated phospholipid micelles and stabilize micellar structure. Philos Trans A Math Phys Eng Sci. 2013;371(2000):20120309.
101. Yang L, Zhong X, Li Q, et al. Potentiation of drug-induced phospholipidosis in vitro through PEGlyated Graphene Oxide as the nanocarrier. Toxicol Sci. 2016 Dec 24;pii:kfw233. [Epub ahead of print].​​
102. Sun W, He S, Martínez-Romero C, et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res. 2017;137:165–172.
103. Gupta-Wright A, Lavers J, Irvine S. Concerns about the off-licence use of amiodarone for Ebola. BMJ. 2015;350:h272.
104. Satolli R. Ebola seen up-close. Eur J Intern Med. 2015;26(2):80–81.
105. Wu L, Dai J, Zhao X, et al. Chloroquine enhances replication of influenza A virus A/WSN/33 (H1N1) in dose-, time-, and MOI-dependent manners in human lung epithelial cells A549. J Med Virol. 2015;87(7):1096–1103.•• An interesting paper reporting the ability of chloroquine to increase viral replication.